Skip to content 
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas. more
| Time Frame | TVRD | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -1.5% | -3.93% | -0.67% |
| 1-Month Return | 5.65% | -2.41% | -1.33% |
| 3-Month Return | -5.98% | 1.64% | -0.29% |
| 6-Month Return | -86.75% | 11.65% | 5.08% |
| 1-Year Return | -72.93% | 3.11% | 19.01% |
| 3-Year Return | -98.91% | 19.21% | 68.62% |
| 5-Year Return | -99.4% | 36.52% | 78.6% |
| 10-Year Return | -98.03% | 126.5% | 240.69% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 135.08M | 23.03M | 41.87M | 20.97M | 7.14M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":17.05,"profit":true},{"date":"2022-12-31","value":30.99,"profit":true},{"date":"2023-12-31","value":15.52,"profit":true},{"date":"2024-12-31","value":5.28,"profit":true}] |
| Cost of Revenue | - | 1.55M | 7.51M | 6.43M | 812.00K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":20.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.61,"profit":true},{"date":"2024-12-31","value":10.81,"profit":true}] |
| Gross Profit | - | 21.47M | 34.35M | 14.54M | 6.33M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":62.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.31,"profit":true},{"date":"2024-12-31","value":18.41,"profit":true}] |
| Gross Margin | - | 93.25% | 82.05% | 69.32% | 88.62% | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":87.99,"profit":true},{"date":"2023-12-31","value":74.34,"profit":true},{"date":"2024-12-31","value":95.04,"profit":true}] |
| Operating Expenses | 128.68M | 110.56M | 121.89M | 136.03M | 62.11M | [{"date":"2020-12-31","value":94.6,"profit":true},{"date":"2021-12-31","value":81.27,"profit":true},{"date":"2022-12-31","value":89.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":45.66,"profit":true}] |
| Operating Income | 5.38M | (89.08M) | (87.53M) | (121.50M) | (55.78M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1654.28,"profit":false},{"date":"2022-12-31","value":-1625.53,"profit":false},{"date":"2023-12-31","value":-2256.17,"profit":false},{"date":"2024-12-31","value":-1035.86,"profit":false}] |
| Total Non-Operating Income/Expense | - | - | 2.71M | 4.30M | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":63.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 7.72M | (88.44M) | (85.47M) | (118.51M) | (71.27M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1145.76,"profit":false},{"date":"2022-12-31","value":-1107.32,"profit":false},{"date":"2023-12-31","value":-1535.34,"profit":false},{"date":"2024-12-31","value":-923.24,"profit":false}] |
| Income Taxes | (691.00K) | - | - | - | (398.00K) | [{"date":"2020-12-31","value":-69100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-39800000,"profit":false}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | - | (20.54M) | (17.35M) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-2054200000,"profit":false},{"date":"2023-12-31","value":-1734700000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | 8.41M | (88.44M) | (85.47M) | (118.51M) | (70.87M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1051.62,"profit":false},{"date":"2022-12-31","value":-1016.34,"profit":false},{"date":"2023-12-31","value":-1409.19,"profit":false},{"date":"2024-12-31","value":-842.65,"profit":false}] |
| EPS (Diluted) | 0.08 | (1.73) | (1.59) | (2.18) | (14.23) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2162.5,"profit":false},{"date":"2022-12-31","value":-1987.5,"profit":false},{"date":"2023-12-31","value":-2725,"profit":false},{"date":"2024-12-31","value":-17786.75,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| TVRD | |
|---|---|
| Cash Ratio | 3.30 |
| Current Ratio | 3.48 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| TVRD | |
|---|---|
| ROA (LTM) | -72.68% |
| ROE (LTM) | -135.64% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| TVRD | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| TVRD | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 1.35 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Tvardi Therapeutics, Inc. (TVRD) share price today is $3.93
Yes, Indians can buy shares of Tvardi Therapeutics, Inc. (TVRD) on Vested. To buy
Yes, you can purchase fractional shares of Tvardi Therapeutics, Inc. (TVRD) via the Vested app. You can start investing in Tvardi Therapeutics, Inc. (TVRD) with a minimum investment of $1.
You can invest in shares of Tvardi Therapeutics, Inc. (TVRD) via Vested in three simple steps:
The 52-week high price of Tvardi Therapeutics, Inc. (TVRD) is $43.65. The 52-week low price of Tvardi Therapeutics, Inc. (TVRD) is $3.5.
The price-to-earnings (P/E) ratio of Tvardi Therapeutics, Inc. (TVRD) is
The price-to-book (P/B) ratio of Tvardi Therapeutics, Inc. (TVRD) is 1.35
The dividend yield of Tvardi Therapeutics, Inc. (TVRD) is 0.00%
The market capitalization of Tvardi Therapeutics, Inc. (TVRD) is $37.71M
The stock symbol (or ticker) of Tvardi Therapeutics, Inc. is TVRD
Consider the share price of Tvardi Therapeutics, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Tvardi Therapeutics, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Tvardi Therapeutics, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Tvardi Therapeutics, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Tvardi Therapeutics, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Tvardi Therapeutics, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
